Gene SRSF1 Reverses Cellular Aging in Mouse Models
The discovery provides a targeted alternative to previous reprogramming methods for delaying age-related decline.
Updated on Oct. 15, 2026 in Life Sciences
Live Poll
Should medical research prioritize the development of new gene therapies to extend human lifespans?
Researchers have identified the gene SRSF1 as a factor capable of reversing cellular aging and reducing chronic inflammation in human skin cells. This research-stage finding, published in Nature Aging, demonstrates that targeted SRSF1 delivery can mitigate aging symptoms in animal models.
Why it matters
The discovery offers a potential alternative to previous, higher-risk cell reprogramming methods by utilizing AI to isolate single genes that influence biological aging. This approach could eventually inform the development of therapies to delay age-related decline in human tissues.
The SRSF1 gene, which regulates the processing of genetic information for protein production, was isolated using an AI model designed to estimate biological age. Researchers delivered the gene to aged mice via a viral vector, resulting in improved DNA repair functions.
The players
Harvard Medical School
An academic medical institution focused on biomedical research and the development of new clinical therapies.
Wyss Institute
A research center at Harvard specializing in biologically inspired engineering and synthetic biology.
The details
Researchers employed an AI model to evaluate gene activity in human skin cells, identifying SRSF1 as a candidate for reversing signs of aging without the complications associated with earlier reprogramming techniques. The study utilized a viral vector — a modified virus stripped of its disease-causing genes — to deliver the SRSF1 genetic cargo to the mice, where it primarily targeted the liver. The intervention effectively activated DNA repair mechanisms, which are often diminished as organisms age.
Timeline
2012: Shinya Yamanaka pioneered early cell reversion techniques.
October 14, 2026: Research findings were published in the journal Nature Aging.
The Tech Race
This development moves beyond the four-gene reprogramming standard established by Shinya Yamanaka in 2012. It represents a shift toward more targeted, single-gene interventions that aim to reduce the systemic risks associated with broad cellular reset programs.
This development is currently in the research stage and does not offer immediate medical treatments for the public. Future progress depends on the successful engineering of safe delivery systems to transport SRSF1 into human tissues.
The takeaway
The study suggests that aging can be treated as a modifiable biological process at the genetic level rather than an inevitable decline. Observers should track upcoming research on human-compatible viral delivery vectors, which are essential for moving these findings out of the laboratory.
Further reading
For broader trends in longevity research, visit the Life Sciences section.
Source note: This article includes information reported by 조선일보.
Live Poll
Should medical research prioritize the development of new gene therapies to extend human lifespans?
